[go: up one dir, main page]

MX2017006563A - Esteroides de 6-alquil-7-hidroxi-4-en-3-ona como intermedios para la produccion de moduladores esteroides del receptor x farnesoide (fxr). - Google Patents

Esteroides de 6-alquil-7-hidroxi-4-en-3-ona como intermedios para la produccion de moduladores esteroides del receptor x farnesoide (fxr).

Info

Publication number
MX2017006563A
MX2017006563A MX2017006563A MX2017006563A MX2017006563A MX 2017006563 A MX2017006563 A MX 2017006563A MX 2017006563 A MX2017006563 A MX 2017006563A MX 2017006563 A MX2017006563 A MX 2017006563A MX 2017006563 A MX2017006563 A MX 2017006563A
Authority
MX
Mexico
Prior art keywords
steroids
intermediates
hydroxy
alkyl
production
Prior art date
Application number
MX2017006563A
Other languages
English (en)
Other versions
MX375863B (es
Inventor
Weymouth-Wilson Alexander
Komsta Zofia
Boydell James
Otter Carl
WALLIS Laura
BATCHELOR Rhys
Original Assignee
Nzp Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1420593.4A external-priority patent/GB201420593D0/en
Priority claimed from GBGB1420594.2A external-priority patent/GB201420594D0/en
Priority claimed from GBGB1505670.8A external-priority patent/GB201505670D0/en
Application filed by Nzp Uk Ltd filed Critical Nzp Uk Ltd
Publication of MX2017006563A publication Critical patent/MX2017006563A/es
Publication of MX375863B publication Critical patent/MX375863B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a compuestos de la fórmula (I), en donde R1, R2, Y, R4 y R5 son como se definen aquí; los compuestos son intermedios en la síntesis de ácidos biliares sintéticos. (ver Fórmula).
MX2017006563A 2014-11-19 2015-11-19 Esteroides de 6-alquil-7-hidroxi-4-en-3-ona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr) MX375863B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1420593.4A GB201420593D0 (en) 2014-11-19 2014-11-19 Compounds
GBGB1420594.2A GB201420594D0 (en) 2014-11-19 2014-11-19 Compounds
GBGB1505670.8A GB201505670D0 (en) 2015-04-01 2015-04-01 Compounds
PCT/GB2015/053516 WO2016079517A1 (en) 2014-11-19 2015-11-19 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators

Publications (2)

Publication Number Publication Date
MX2017006563A true MX2017006563A (es) 2018-01-26
MX375863B MX375863B (es) 2025-03-07

Family

ID=54704019

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006563A MX375863B (es) 2014-11-19 2015-11-19 Esteroides de 6-alquil-7-hidroxi-4-en-3-ona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr)

Country Status (15)

Country Link
US (1) US10301350B2 (es)
EP (1) EP3221331B1 (es)
JP (1) JP6700274B2 (es)
KR (1) KR102526631B1 (es)
CN (1) CN107207559B (es)
BR (1) BR112017010319B1 (es)
CA (1) CA2968309A1 (es)
DK (1) DK3221331T3 (es)
EA (1) EA033427B1 (es)
ES (1) ES2759725T3 (es)
MX (1) MX375863B (es)
PL (1) PL3221331T3 (es)
PT (1) PT3221331T (es)
TW (1) TWI690536B (es)
WO (1) WO2016079517A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107207558B (zh) 2014-11-19 2019-10-29 Nzp英国有限公司 作为制备类固醇FXR调节剂的中间体的6α-烷基-6,7-二酮类固醇
CN107108688B (zh) 2014-11-19 2019-10-29 Nzp英国有限公司 作为制备类固醇FXR调节剂的中间体的6α-烷基-3,7-二酮类固醇
PL3221332T3 (pl) 2014-11-19 2019-10-31 Nzp Uk Ltd Steroidy, 5.beta.-6-alkilo-7-hydroksy-3-ony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr
CZ2015504A3 (cs) * 2015-07-16 2017-01-25 Zentiva, K.S. Krystalické formy obeticholové kyseliny
CN108495858A (zh) * 2015-12-22 2018-09-04 英特塞普特医药品公司 奥贝胆酸的多晶结晶形式
GB201608776D0 (en) * 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608779D0 (en) * 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608777D0 (en) * 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
JP7057783B2 (ja) * 2016-11-29 2022-04-20 エナンタ ファーマシューティカルズ インコーポレイテッド スルホニル尿素胆汁酸誘導体の調製方法
EP3431486A1 (en) * 2017-07-18 2019-01-23 Bionice, S.L.U. Process and intermediates for the synthesis of obeticholic acid and derivatives thereof
CN111138509B (zh) * 2018-11-02 2022-12-06 东莞东阳光药物研发有限公司 奥贝胆酸的制备方法
CN112521438B (zh) * 2020-12-08 2021-11-23 苏利制药科技江阴有限公司 一种β-谷甾醇的合成工艺
WO2023288123A1 (en) * 2021-07-16 2023-01-19 Interecept Pharmaceuticals, Inc. Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid
CN113912661B (zh) * 2021-11-11 2023-04-21 湖南科瑞生物制药股份有限公司 一种7-羟基甾体化合物的合成方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2624748A (en) 1950-09-09 1953-01-06 Upjohn Co Bisnorchola-4, 6-dien-3-one-22-al
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
JPH07505915A (ja) 1992-04-14 1995-06-29 コーネル　リサーチ　ファウンデーション、インコーポレーテッド 樹枝状巨大分子およびその製造法
AU6392894A (en) 1993-02-26 1994-09-14 Magainin Pharmaceuticals, Inc. Chemical synthesis of squalamine
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
JP4021327B2 (ja) 2001-03-12 2007-12-12 インターセプト ファーマスーティカル インコーポレイテッド Ｆｘｒに対する作用薬としてのステロイド
US20090062256A1 (en) 2001-06-01 2009-03-05 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
KR100948532B1 (ko) 2001-11-07 2010-03-23 넥타르 테라퓨틱스 분지형 중합체 및 그의 공액체
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
JP2007210888A (ja) * 2006-01-12 2007-08-23 Mitsubishi Chemicals Corp ステロイド化合物の製造方法
EP1987051A2 (en) 2006-02-14 2008-11-05 Intercept Pharmaceuticals, Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions
CA2656320C (en) 2006-06-27 2015-04-28 Intercept Pharmaceuticals, Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions
BRPI0808684B1 (pt) 2007-01-19 2021-08-10 Intercept Pharmaceuticals, Inc Compostos moduladores de tgr5, composição e seus usos
CN105037476B (zh) 2008-07-30 2018-06-12 英特塞普特医药品公司 Tgr5调节剂及其使用方法
KR101667436B1 (ko) 2008-11-19 2016-10-18 인터셉트 파마슈티컬즈, 인크. Ｔｇｒ５ 조절제 및 그의 사용 방법
US8999964B2 (en) * 2008-11-19 2015-04-07 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
US8829213B2 (en) 2009-07-29 2014-09-09 The University Of Chicago Liver X receptor agonists
HK1211296A1 (en) 2012-06-19 2016-05-20 英特塞普特医药品公司 Preparation, uses and solid forms of obeticholic acid
BR112015009395A2 (pt) 2012-10-26 2017-07-04 Intercept Pharmaceuticals Inc processo para preparação de derivados do ácido biliar
HK1211844A1 (en) 2012-11-28 2016-06-03 英特赛普特医药品公司 Treatment of pulmonary disease
US20140206657A1 (en) 2013-01-18 2014-07-24 City Of Hope Bile acid analog tgr5 agonists
MX352065B (es) 2013-05-14 2017-11-08 Intercept Pharmaceuticals Inc Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoidex.
CA2913108A1 (en) 2013-05-24 2014-11-27 Nestec S.A. Pathway specific assays for predicting irritable bowel syndrome diagnosis
WO2015183794A1 (en) 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
AU2015265893B2 (en) 2014-05-29 2020-11-12 Bar Pharmaceuticals S.R.L. Cholane derivatives for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases
HK1243930A1 (zh) 2014-11-06 2018-07-27 英安塔制药有限公司 作爲fxr/tgr5激動劑的膽汁酸類似物和其使用方法
PL3221332T3 (pl) 2014-11-19 2019-10-31 Nzp Uk Ltd Steroidy, 5.beta.-6-alkilo-7-hydroksy-3-ony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr
CN107207558B (zh) 2014-11-19 2019-10-29 Nzp英国有限公司 作为制备类固醇FXR调节剂的中间体的6α-烷基-6,7-二酮类固醇
CN107108688B (zh) 2014-11-19 2019-10-29 Nzp英国有限公司 作为制备类固醇FXR调节剂的中间体的6α-烷基-3,7-二酮类固醇
WO2016086134A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
BR112017010893A2 (pt) 2014-11-26 2018-02-06 Enanta Pharm Inc análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
CN106279328A (zh) 2015-05-20 2017-01-04 重庆药友制药有限责任公司 一种制备6α-烷基鹅去氧胆酸的方法
CN107771180B (zh) 2015-06-19 2021-03-23 英特塞普特医药品公司 Tgr5调节剂及其使用方法
CN106397522A (zh) 2015-07-31 2017-02-15 中国人民解放军军事医学科学院毒物药物研究所 3,7‑二（叔丁基二甲基硅基氧基）‑6‑烯‑5β‑胆烷‑24‑酸甲酯
CN106478759A (zh) 2015-08-31 2017-03-08 陕西合成药业股份有限公司 奥贝胆酸衍生物及其制备方法和用途
CN106478756A (zh) 2015-09-02 2017-03-08 中美华世通生物医药科技（武汉）有限公司 Oca-e单晶及其制备方法和用途
CN106518946A (zh) 2015-09-10 2017-03-22 上海迪诺医药科技有限公司 磺酰脲衍生物、其药物组合物及应用

Also Published As

Publication number Publication date
EA033427B1 (ru) 2019-10-31
NZ731924A (en) 2020-12-18
US10301350B2 (en) 2019-05-28
BR112017010319B1 (pt) 2023-04-11
BR112017010319A2 (pt) 2017-12-26
MX375863B (es) 2025-03-07
CN107207559B (zh) 2019-10-25
PL3221331T3 (pl) 2020-03-31
CN107207559A (zh) 2017-09-26
WO2016079517A1 (en) 2016-05-26
DK3221331T3 (da) 2019-12-02
CA2968309A1 (en) 2016-05-26
JP6700274B2 (ja) 2020-05-27
KR102526631B1 (ko) 2023-04-27
TW201632537A (zh) 2016-09-16
EP3221331B1 (en) 2019-09-18
JP2017534670A (ja) 2017-11-24
PT3221331T (pt) 2019-12-23
US20170327528A1 (en) 2017-11-16
HK1246801A1 (en) 2018-09-14
EA201790884A8 (ru) 2019-07-31
EP3221331A1 (en) 2017-09-27
ES2759725T3 (es) 2020-05-12
EA201790884A1 (ru) 2017-11-30
TWI690536B (zh) 2020-04-11
KR20170086604A (ko) 2017-07-26

Similar Documents

Publication Publication Date Title
MX2017006563A (es) Esteroides de 6-alquil-7-hidroxi-4-en-3-ona como intermedios para la produccion de moduladores esteroides del receptor x farnesoide (fxr).
MX2017006565A (es) Esteroides 6.alfa.-alquil-3,7-diona como intermedios para la produccion de moduladores esteroides del receptor x farnesoide (fxr).
MX2017006567A (es) Esteroides 6.alfa.-alquil-6,7-diona como intermedios para la produccion de moduladores esteroides del receptor x farnesoide (fxr).
EA201790881A8 (ru) 5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
EA201992183A2 (ru) Синтез полициклических карбамоилпиридоновых соединений
GR20140100479A (el) Συνθεση λιραγλουτιδης
MX2015016535A (es) Metodo de produccion para tagatosa.
UY36499A (es) Uso de picolinamidas como fungicidas
CR20150117A (es) Derivados c17-alcandilo y alquendilo del ácido oleanólico y sus métodos de uso
MX378186B (es) Cristales novedosos de 9-etil-6,6-dimetil-8-(4-morfolin-4-il-piperidin-1-il)-11-oxo-6,11-dihidro-5h-benzo[b]carbazol-3-carbonitrilo.
UY35305A (es) Compuestos sustituidos como moduladores de la pro teína de activación de la 5-lipoxigenasa (flap)
MX2015013792A (es) Sonda fluorescente estañosa.
MX2016000551A (es) Proceso novedoso para la preparacion de pirrolidina-dionas espiroheterociclicas.
CR20160448A (es) Nuevos derivados de piridina
MX389099B (es) Proceso para la preparación de 3-cloro-2-vinilfenilsulfonatos.
MX382659B (es) Proceso para la preparación de derivados de tiazol.
MX2016015623A (es) Proceso para la preparacion de derivados dihidroisoxazol.
BR112019002828A2 (pt) método de preparação de derivados de estireno substituído
IN2014MU00171A (es)
MX2018009943A (es) Proceso para la fabricacion de derivados de 3-piperazin-1-il-propi lamina.
BR112017018992A2 (pt) processo de preparação de derivados de fenilisoxazolina substituída

Legal Events

Date Code Title Description
FG Grant or registration